PE39996A1 - TREATMENT OF NICOTINE ANSIA AND / OR SMOKING ABSENCE SYMPTOMS - Google Patents

TREATMENT OF NICOTINE ANSIA AND / OR SMOKING ABSENCE SYMPTOMS

Info

Publication number
PE39996A1
PE39996A1 PE1995272089A PE27208995A PE39996A1 PE 39996 A1 PE39996 A1 PE 39996A1 PE 1995272089 A PE1995272089 A PE 1995272089A PE 27208995 A PE27208995 A PE 27208995A PE 39996 A1 PE39996 A1 PE 39996A1
Authority
PE
Peru
Prior art keywords
nicotine
ansia
smoking
symptoms
absence
Prior art date
Application number
PE1995272089A
Other languages
Spanish (es)
Inventor
Satyanarayana Majeti
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE39996A1 publication Critical patent/PE39996A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

QUE COMPRENDE : A) DE 0,1 gm A 2 mg DE NICOTINA, B) DE 3 mg A 20 mg DE CAFEINA O EQUIVALENTE DE CAFEINA XANTINA; C) UNO O MAS VEHICULOS FARMACEUTICAMENTE ACEPTABLES ADECUADOS PARA LA ADMINISTRACION NASAL DIRECTA O INDIRECTA, D) UNO O MAS COMPUESTOS AROMATICOS SELECCIONADOS DEL GRUPO QUE CONSISTE DE MENTOL, EUCALIPTOL, TIMOL, ACEITE DE HOJA DE CEDRO, ACEITE DE MIRISTICA, ACEITE DE LAVANDA, ACEITE DE NUEZ MOSCADA, TREMENTINA, Y MEZCLAS DE ESTOS, E) DE 0.01% A 5% DE UN HUMECTANTE; Y F) DE 0,5% A 10% DE UN AGENTE TENSOACTIVO . EN DONDE LA COMPOSICION SE ENCUENTRA EN FORMA DE UNA EMULSION CON BASE DE UNGUENTO, DE UN GEL NASAL, EN FORMA DE SOLIDO EN DONDE SE INHALAN LOS VAPORES DEL SOLIDOWHAT IT INCLUDES: A) FROM 0.1 gm TO 2 mg OF NICOTINE, B) FROM 3 mg TO 20 mg OF CAFFEINE OR THE EQUIVALENT OF CAFFEINE XANTHINE; C) ONE OR MORE PHARMACEUTICALLY ACCEPTABLE VEHICLES SUITABLE FOR DIRECT OR INDIRECT NASAL ADMINISTRATION, D) ONE OR MORE SELECTED AROMATIC COMPOUNDS FROM THE GROUP WHICH CONSISTS OF MENTOL, EUCALIPTOL, TIMOL, ACEITE DE LEAF, CEDAR NUT OIL, TREMENTINE, AND MIXTURES OF THESE, E) FROM 0.01% TO 5% OF A HUMIDANT; AND F) FROM 0.5% TO 10% OF A SURFACE AGENT. WHERE THE COMPOSITION IS IN THE FORM OF AN UNGUENT-BASED EMULSION, A NASAL GEL, IN THE FORM OF A SOLID WHERE THE VAPORS OF THE SOLID ARE INHALED

PE1995272089A 1994-06-23 1995-06-22 TREATMENT OF NICOTINE ANSIA AND / OR SMOKING ABSENCE SYMPTOMS PE39996A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26466694A 1994-06-23 1994-06-23

Publications (1)

Publication Number Publication Date
PE39996A1 true PE39996A1 (en) 1996-10-03

Family

ID=23007084

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995272089A PE39996A1 (en) 1994-06-23 1995-06-22 TREATMENT OF NICOTINE ANSIA AND / OR SMOKING ABSENCE SYMPTOMS

Country Status (6)

Country Link
AU (1) AU2702795A (en)
IL (1) IL114130A0 (en)
MA (1) MA23586A1 (en)
PE (1) PE39996A1 (en)
WO (1) WO1996000069A1 (en)
ZA (1) ZA955033B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
AUPO108596A0 (en) * 1996-07-18 1996-08-08 Collier, Gregory Treatment of obesity
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
WO2004104490A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Self-contained heating unit and drug-supply unit employing same
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778677A (en) * 1981-07-09 1988-10-18 Ebbesen Gerald K Method for treatment of nicotine craving
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
DE3506406A1 (en) * 1985-02-23 1986-08-28 Hans-Josef 5600 Wuppertal Stromberg DEVICE FOR THE DEWNING OF EATING, DRINKING, SMOKING AND / OR ADDICTIVE Habits
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4959380A (en) * 1988-12-19 1990-09-25 Wilson Jordan E Method of treating people to stop smoking and composition
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency

Also Published As

Publication number Publication date
ZA955033B (en) 1996-02-15
WO1996000069A1 (en) 1996-01-04
MA23586A1 (en) 1995-12-31
IL114130A0 (en) 1995-10-31
AU2702795A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
BR9812615A (en) Pharmaceutical compositions to treat tobacco addiction or nicotine addiction, to relieve symptoms of nicotine withdrawal or to facilitate smoking cessation, to treat cocaine addiction and associated withdrawal effects, to treat alcohol dependence and associated withdrawal effects, and , processes to treat tobacco addiction or nicotine addiction, to relieve nicotine withdrawal symptoms or to facilitate smoking cessation, to treat cocaine addiction and associated withdrawal effects, and to treat alcohol dependence and associated withdrawal effects
BRPI0317463B8 (en) compound, pharmaceutical composition comprising the same and use of said compound in the preparation of a medicament for treating a transthyretin amyloid disease
ES2162615T3 (en) METHOD TO TREAT OR PREVENT TYPE 1 DIABETES THROUGH ORAL INSULIN ADMINISTRATION.
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
ES2135460T3 (en) COMPOSITION TO HELP STOP SMOKING.
ES2004856A4 (en) NATURAL PULMONARY TENSIOACTIVE AGENT, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS.
NL194748B (en) Osmotic dosage form for treatment of cardiovascular diseases.
ES2160707T3 (en) COMPOSITIONS THAT INCLUDE DETERIORATING AGENTS OF DNA AND P53.
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
FI963696A (en) Gel for skin disease therapy and skin disinfection
NO990595D0 (en) Use of the clikinol chelating agent in the preparation of a pharmaceutical composition for the treatment of Alzheimer's disease
DE68924537D1 (en) COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO.
PE39996A1 (en) TREATMENT OF NICOTINE ANSIA AND / OR SMOKING ABSENCE SYMPTOMS
BR0010515A (en) Transdermal delivery therapeutic system, process for masking an unpleasant odor and use of an essential oil in a transdermal delivery therapeutic system
PE11399A1 (en) COMBINATION OF LORATADINE AND A DECONESCENTANT FOR THE TREATMENT OF ASTHMA
PT90249A (en) METHOD FOR THE USE OF 3-SUBSTITUTED 2-OXINDOLE-1-CARBOXAMIDES FOR T-CELL BLENDING
BR0311747A (en) Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease
PE20040080A1 (en) COMBINATIONS OF EPINASTIN, BELLADONE AND PSEUDOEFHRIN AS NEW PHARMACEUTICAL FORMULATIONS
NO20012310D0 (en) Optically active pyridyl-4H-1,2,4-oxazdiazine derivative and its use in the treatment of vascular disease
PE33396A1 (en) COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS
ES2039433T3 (en) A PHARMACEUTICAL FORMULATION.
IT1241079B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCEDURE FOR THEIR PREPARATION AND RELATED THERAPEUTIC USE
BR9802153A (en) Method of obtaining and using the extract of rosmarinus officinalis, in the treatment of various diseases.
BR0109770A (en) Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease
NO990450L (en) Treatment of mental disorders

Legal Events

Date Code Title Description
FD Application declared void or lapsed